3SOF

YMI: Octagon Starts @ Buy; Sets Tgt @ $9.5
Wednesday, April 26, 2006 09:51 ET

Issuer: YM Biosciences, Inc. (AMEX: YMI)

Analyst Firm: Octagon

Ratings Action: INITIATE

Current Rating: Buy

Target Price Action: INITIATE
Target Price: $9.50

This rating information was reported by Dow Jones Newswire.


http://www.knobias.com/individual/public/news.htm?eid=3.1.b7001d504dec6c2ee49fa4 2b52c8f66cabc8e326316490948102cb623a840ef0

YM BioSciences anticancer product enters phase III in Europe
Friday , April 28, 2006 13:00 ET

Apr 28, 2006 (Datamonitor via COMTEX) -- YM BioSciences partner Oncoscience AG has begun treating patients in its phase III trial of nimotuzumab in combination with radiation for the treatment of children with brain cancer.

The trial is a single arm study in which 40 children with inoperable pontine (brain stem) glioma will be treated with radiation concomitant with nimotuzumab. The primary clinical endpoints in the trial will be progression-free survival with median survival as secondary endpoint.

Clinical sites will be located in Germany, Italy, Belarus and Russia and it is anticipated that recruitment could be complete within approximately 12 months after the start of patient enrolment.

YM BioSciences is also undertaking the clinical development of nimotuzumab in non-small cell lung cancer. While CIMAB SA

YM's licensor, CIMAB SA and its parent, the Center for Molecular Immunology, are conducting trials with nimotuzumab in glioma, breast, esophageal, uterine cervix, prostate and head and neck cancer.

upgrade:
YMI: Canaccord Adams Ups to Buy from Hold; Analyst Notes
Wednesday, May 03, 2006 11:54 ET
Issuer: YM Biosciences, Inc. (AMEX: YMI)
Analyst Firm:  Canaccord Adams
Ratings Action: UPGRADE
Current Rating: Buy (from Hold)
Analyst Comments: The firm cites valuation as basis for their upgrade.

TA breakout soon IMO 

please read carefully:
http://www.ymbiosciences.com/downloads/Q2_2006.pdf
&
http://www.ymbiosciences.com/downloads/2006_final_prospectus.pdf

feedback is appreciated
tia
OLIVER

M BioSciences hits data milestone
Wednesday, June 07, 2006 11:54 ET

By Staff Reporter

NEW YORK, Jun 07, 2006 (XFN-ASIA via COMTEX) -- Cancer drug developer YM BioSciences Inc. said Wednesday that it reached the first analysis milestone in its late-stage clinical trial for its breast cancer drug tesmilifene.

In a 700-patient clinical trial, 192 patients with late stage breast cancer have died, triggering an analysis of data comparing the survival benefit of tesmilifene and cancer drugs epirubicin and cyclophosphamide against the cancer drugs alone. The Mississauga, Ontario-based company said the analysis will occur within the next four weeks.

The company hopes to show that tesmilifene allowed patients to live 33 percent longer, based on 384 patient deaths. Under the trial design, if the analysis of 192 deaths shows that tesmilifene increased patient's survival by 50 percent, the study can be stopped early, and all subjects can be treated with tesmilifene.

The drug is under a Food and Drug Administration fast-track designation, meaning the company can submit data to the agency and receive feedback as data becomes available.

YM BioSciences shares fell 10 cents, or 2 percent, to $4.88 in morning trading on the American Stock Exchange.

YM BioSciences Cancer Trial to Continue
Tuesday August 22, 6:20 pm ET
Independent Board Recommends YM BioSciences Continue Trial of Breast Cancer Treatment

NEW YORK (AP) -- Canadian drug developer YM BioSciences Inc. said Tuesday an independent data safety monitoring board recommended a late-stage trial of its tesmilifene breast cancer treatment continue.

YM BioSciences is conducting a Phase III trial of tesmilifene for the treatment of rapidly progressing metastatic or recurrent breast cancer. The trial, which enrolled 723 patients in September 2005, is the subject of a Special Protocol Assessment and a Fast Track designation for advanced breast cancer by the Food and Drug Administration.

"Based on the study design, we believe the trial continues to have the prospect to yield a positive outcome," Chairman and Chief Executive David Allan said in a statement. "Further, this analysis also confirms that tesmilifene continues to demonstrate a good safety profile."

YM BioSciences shares rose 62 cents, or 20.7 percent, to $3.61 in aftermarket trading on the INET electronic exchange, after they closed up a penny at $2.99 on the Nasdaq. Shares have traded between $2.35 and $6.50 over the past year.

no news, but nice chart

YM BioSciences provides update on tesmilifene pivotal trial
Monday January 15, 12:30 am ET

MISSISSAUGA, ON, Jan. 15 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the independent Data Safety Monitoring Board (DSMB) for the pivotal Phase III trial of tesmilifene in patients with metastatic or recurrent breast cancer has notified the Company that the milestone of 320 events required for the third interim analysis in its pivotal Phase III trial has occurred.

Since the last "data sweep" was completed in November 2006, the DSMB advised the Company to conduct a further data sweep to bring the survival data current prior to performing the third interim analysis. This data sweep is ongoing and the Company expects this work to be completed and to have a formal recommendation from the DSMB in February 2007. A data sweep is conducted on a periodic basis prior to each interim analysis.

"Although we are eager to learn the outcome of this third interim analysis, a meticulous review by the DSMB of any new data is entirely in keeping with the rigor of this trial," said David Allan, Chairman and CEO of YM BioSciences. "Because of the interest in this third analysis and expectations that it might occur this month, we decided to confirm that the threshold number of events has been reached. We have no additional information from this trial at this time."

The pivotal Phase III trial compares the survival of patients treated with tesmilifene combined with epirubicin/cyclophosphamide to epirubicin/cyclophosphamide alone in women with rapidly progressing metastatic and/or recurrent breast cancer. The trial, which completed enrollment of 723 patients in September 2005, is the subject of a Special Protocol Assessment and a Fast Track designation for advanced breast cancer by the FDA.

The trial is being conducted according to a sequential design that permits a number of planned interim analyses and the trial will continue until one of two specific statistical conditions is satisfied. At each analysis, the hazard ratio between the tesmilifene-containing treatment arm and the control arm is calculated and then reviewed by the DSMB. The trial may be concluded if either the tesmilifene-containing treatment arm is superior to the control by a specified margin or it is determined that such evidence is not going to be found. If the evidence is insufficient for either conclusion to be drawn, then the trial continues until the next analysis. At the first and second interim analyses, the DSMB recommended that the trial continue as planned.

 
YM BioSciences Halts Breast Cancer Trial
Tuesday January 30, 5:32 pm ET
YM BioSciences Says Independent Board Doesn't See Benefit of Continuing Study; Shares Plunge

NEW YORK (AP) -- Canadian cancer drug developer YM BioSciences Inc. said Tuesday an independent safety monitoring board advised the company to halt its late-stage trial of tesmilifene in breast cancer patients, because it doesn't believe there will be significant survival benefits to taking the drug over other treatments.

Shares of YM plunged $1.12, or nearly 30 percent, to $2.65 in aftermarket trading, having closed up 4 cents at $3.77 on the American Stock Exchange.

The Mississauga, Ontario-based company said the trial isn't being stopped due to safety concerns relating to the product, and plans to submit data from the trial to a medical meeting after a review is complete.

The trial compared the survival of 723 women with rapidly spreading and/or recurrent breast cancer treated with either tesmilifene combined with epirubicin/cyclophosphamide or epirubicin/cyclophosphamide alone. The study was the subject of a "Fast-Track" designation for advanced breast cancer by the Food and Drug Administration.

"We are very disappointed by this outcome and will be evaluating the data to understand why tesmilifene did not add a clinical benefit in this trial," said David Allan, chairman and CEO of YM BioSciences. "Upon completing the review of the Phase III data, the company will consider its options relating to tesmilifene."

Tesmilifene is a small molecule that selectively targets multiple-drug resistant tumor cells, sensitizing them to chemotherapy.

down 52% now